Novartis: Primary Myelofibrosis trials

The registry lists 24 Primary Myelofibrosis studies with Novartis as lead sponsor. 2 are open to participants now and 13 have results posted.

Phase 1 7Phase 2 7Phase 3 7Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingNCT07357727Phase 3
• Managed Access Programs for INC424, RuxolitinibAvailableNCT04745637
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active, not recruitingNCT04603495Phase 3Results posted
• Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsTerminatedNCT04097821Phase 1/2Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFCompletedNCT01392443Phase 2Results posted
• Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialCompletedNCT00934544Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary MyelofibrosisTerminatedNCT00931762Phase 2Results posted
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
• A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in TurkeyCompletedNCT07357441
• Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruitingNCT07340138Phase 1
• A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
• Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
• Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With MyelofibrosisCompletedNCT02370706Phase 1
• A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary MyelofibrosisTerminatedNCT01730248Phase 1
• Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
• Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2